Erratum: Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial (American Journal of Psychiatry DOI: 10.1176/appi.ajp.2019.18101191)

When the article "Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo- Controlled Trial," by Yasmin L. Hurd, Ph.D., et al. (doi: 10.1176/appi.ajp.2019.18101191) was published online on May 21, 2019 and subsequently appeared as part of the November 2019 issue, there was an error in the adverse events reported in Table S4 of the data supplement. For Test Session 2 (Day 2), there were two "tired/fatigue" reports in the placebo group and none in the 800 mg cannabidiol group; also for Test Session 2 (Day 2), it should have been noted that one person accounted for the events reported in the 400 mg group. The data supplement was replaced with these changes incorporated on June 9, 2020.